| VVOS 0.1638 -16.43% | CLGN 0.3879 8.35% | PCG 13.3 0.23% | GPRO 0.8762 46.06% | AIM 0.2407 6.50% | NVDA 216.77 -1.82% | TSLL 9.6 -3.71% | CNH 11.81 -0.17% | RDHL 0.9 36.16% | NVD 4.07 3.56% | NU 14.425 -0.86% | BITO 10.475 -1.46% | COOT 0.5432 -8.37% | AAL 13.2 -1.71% | FNGR 0.223 -43.97% | INTC 86.97 -2.84% | SOAR 0.2151 -7.48% | NCRA 2.32 -18.02% | SPCX 141.73 -1.36% | TSLA 360.91 -1.91% | PATH 18.35 -1.61% | LGCL 0.0351 -9.77% | ABEV 2.87 0.35% | AEHL 6.49 83.33% | PFE 28.8 1.19% | AMZN 254.87 -1.89% | NIO 4.075 -3.89% | NOK 10.055 -0.84% | BAC 61.94 -0.61% | SNAP 5.55 2.21% | KEEL 3.04 -3.49% | IBIT 44.075 -1.33% | TQQQ 69.07 -3.96% | WETO 7.67 39.96% | BMNR 24.45 -3.44% | AAPL 317 0.05% | PURR 11.73 -4.24% | F 13.94 0.43% | WBUY 0.8 -11.11% | ROIV 34.63 -0.03% | IREN 36.11 -2.72% | CDE 19.79 -4.76% | SPY 761.97 -0.66% | IONQ 39.31 0.28% | T 26.15 1.00% | HYG 79.2 -0.21% | SOFI 17.53 -1.96% | TLT 81.895 -0.76% | SLB 60.1 4.83% | PLUG 2.11 -2.31%

AngioDynamics, Inc. (NASDAQ: ANGO) Surpasses Q1 Fiscal 2026 Earnings Expectations

AngioDynamics, Inc. (NASDAQ:ANGO), a prominent figure in the medical technology industry, focuses on improving vascular blood flow and expanding cancer treatment options. The company's recent first-quarter fiscal 2026 earnings showcased a narrower-than-expected loss per share of $0.10, surpassing the Zacks Consensus Estimate of a $0.14 loss. This performance indicates an improvement from the previous year's adjusted loss of $0.11 per share.

ANGO's revenue for the quarter was $75.71 million, slightly below the estimated $75.94 million but still represents a 12.2% increase from the previous year. This growth was significantly propelled by a 26.1% increase in its Med Tech segment. Following these results, AngioDynamics' CEO, Jim Clemmer, announced an upward revision of the fiscal year 2026 sales outlook to a range of $308 million to $313 million.

The company's pro-forma adjusted figures, excluding the impact of divested businesses and discontinued products, revealed a GAAP loss per share of $0.26, an improvement from the previous year's loss of $0.32. Despite a negative price-to-earnings (P/E) ratio of -14.44, AngioDynamics maintains a strong liquidity position with a current ratio of 2.29, indicating it has more than twice the amount of current assets compared to its current liabilities.

Following the earnings report, AngioDynamics' stock experienced a significant surge of 10.5% by 11:25 a.m. ET, reflecting investor confidence in the company's performance and future prospects. The company's gross profit margin increased to 55.3%, 90 basis points higher than the previous year, although the GAAP-calculated earnings were lower than the $0.10 per-share adjusted profit.

Despite financial ratio challenges, such as a price-to-sales ratio of 1.53 and an enterprise value to operating cash flow ratio of -49.91, AngioDynamics continues to focus on its core operations. The company's ongoing efforts to improve patient quality of life and expand its medical technology offerings are key drivers of its current momentum and future growth potential.

Published on: October 7, 2025